Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Wasatch Micro Cap Fund 2026 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (Wasatch Micro Cap Fund)

Primary Source Intelligence • Q3 2026 Letter Analysis

Wasatch Micro Cap Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Wasatch Micro Cap Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD-12.16%

Annualized+11.04%

Positioning StanceCAUTIOUS

Market CapMicroCap

GeographyUS

Digest Analysis

Quick Take

"Constructive on cash-generative microcap compounders with self-funding growth models, reducing discretionary consumer exposure while consolidating trade education into $UTI and holding high-conviction infrastructure and identity software leaders."

Executive Summary

During the third quarter of 2026, the Wasatch Micro Cap Fund (Investor Class) delivered a net return of -12.16%, performing closely in line with the benchmark Russell Microcap Growth Index, which returned -12.15% net of fees. Relative performance was aided by positive stock selection within information technology and financials, but was dampened by adverse positioning in consumer discretionary, industrials, and materials. In response to tightening financial conditions, the strategy actively reduced consumer-oriented cyclical exposures while maintaining selective allocations to cash-generative businesses capable of self-funding growth. The investment environment was defined by macroeconomic headwinds including rising interest rates, lingering inflation concerns, geopolitical friction, and a broader correction across equities tied to the artificial intelligence buildout. The fund maintained an intentional underweight to cash-burning biotechnology companies within healthcare, seeking instead to reposition into profitable medical equipment and device makers, while leveraging financial holdings that benefit from rising yields on cash reserves. Key individual contributors included AOTI and Red Violet (RDVT), the latter benefiting from robust earnings execution and high operating leverage in identity intelligence. Conversely, performance was weighed down by ready-mix concrete provider Suncrete (RMIX) and specialty contractor Orion Group Holdings (ORN) due to severe regional weather and pushouts in data center construction schedules. Additionally, the managers exited Lincoln Educational Services (LINC) following enrollment decelerations, consolidating trade school exposure into Universal Technical Institute (UTI).

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

62%

CautiousHigh

Moderate (62%)

Position sizing is balanced across an extensive microcap roster, with top holdings like RDVT and Suncrete capped around 4.0%. Conviction is expressed through willingness to hold through weather-related headwinds in infrastructure names, but tempered by broader microcap diversification.

Growth Outlook

45%

BearishBullish

Neutral (45%)

The managers emphasize macroeconomic headwinds such as persistent inflation, elevated interest rates, and consumer stress that led to double-digit benchmark index losses during the quarter. However, they view microcaps generating self-funded cash flows as well positioned to navigate rate headwinds.

Risk Appetite

42%

DefensiveAggressive

Balanced (42%)

The team actively reduced exposure to consumer-facing stocks and avoided unprofitable biotechnology companies, rotating capital into defensive, cash-generative businesses and higher-yielding financial institutions.

Capital Deployment

50%

De-riskingDeploying

Net Neutral (50%)

Capital deployment remained broadly neutral as the fund balanced trimming consumer discretionary and unviable education holdings against selective additions in healthcare and financial holdings.

Forward Guidance

58%

CautiousExpansionary

Neutral (58%)

The managers are actively evaluating selective re-entry opportunities in healthcare equipment and device makers while consolidating thematic exposure into more diversified platforms like UTI.

Language Signal

48%

BearishBullish

Balanced (48%)

The letter balances headwinds like inflation, interest rates, weather disruptions, and tech pullbacks with positive fundamental notes around market share expansion, operating leverage, and earnings outperformance in core holdings.

Perceived Risk

68%

Low RiskElevated

Elevated Risk (68%)

The managers highlight meaningful macroeconomic and systemic challenges including energy price shocks, stressed consumers, power grid bottlenecks, and unpredictable weather events that directly affected portfolio holdings.

Opportunity Density

52%

ScarceAbundant

Selective (52%)

Compelling microcap ideas are deemed selective rather than ubiquitous, with the team focusing tightly on profitable niches and companies possessing localized monopoly pricing power.

Time Horizon

72%

Short-TermLong-Term

Decade+ (72%)

The fund emphasizes durable competitive moats, roll-up compounders, and multi-year organic growth runs rather than short-term quarterly trading catalysts.